The Utility of Inflammatory Serum Markers in the Assessment of Perioperative Morbidity after Radical Cystectomy for Bladder Cancer
Author:
Claps Francesco12ORCID, Rossin Giulio1, van Rhijn Bas W. G.2, Mir Maria Carmen3, Mertens Laura S.2, Ongaro Luca1ORCID, Traunero Fabio1ORCID, Iachimovsky Alexandra I.1, Piasentin Andrea1ORCID, Vedovo Francesca1, Perotti Alessandro4ORCID, Tulone Gabriele5ORCID, Zucchi Alessandro4ORCID, Liguori Giovanni1, Simonato Alchiede5ORCID, Bartoletti Riccardo4, Trombetta Carlo1ORCID, Pavan Nicola5ORCID
Affiliation:
1. Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, 34149 Trieste, Italy 2. Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands 3. Department of Urology, Hospital Universitario La Ribera, 46600 Valencia, Spain 4. Department of Translational Research and New Technologies, University of Pisa, 56126 Pisa, Italy 5. Urology Clinic, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, 90133 Palermo, Italy
Abstract
Background and Objectives: To date, sparse evidence exists about the impact of inflammatory serum markers in predicting perioperative complications after radical cystectomy (RC) for bladder cancer (BC). Here, we evaluated the role of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), C-reactive protein (CRP), and plasma fibrinogen in predicting perioperative morbidity and unplanned 30-days readmission after RC for BC. Materials and methods: We relied on a collaborative database of 271 patients who underwent open RC for cT1-4a N0 M0 BC between January 2012 and December 2022. Univariable and multivariable binomial logistic regression analyses were performed to assess the odds ratio (OR) with 95% confidence intervals (CI) testing the ability of each serum marker to predict postoperative complications (any-grade and major complications), and 30-days unplanned readmission. Results: The median age at RC was 73 yr (IQR 67–79). A total of 182 (67.2%) patients were male and the median BMI was 25.2 (IQR 23.2–28.4). Overall, 172 (63.5%) patients had a Charlson Comorbidity Index (CCI) greater than 2 points and 98 (36.2%) were current smokers at the time of RC. Overall, 233 (86.0%) patients experienced at least one complication after RC. Of these, 171 (63.1%) patients had minor complications (Clavien–Dindo grade 1–2) while 100 (36.9%) experienced major complications (Clavien–Dindo grade ≥ 3). According to multivariable analysis, current smoking status, high plasma fibrinogen, and preoperative anemia were independently associated with major complications (OR 2.10, 95%CI 1.15–4.90, p = 0.02), (OR 1.51, 95%CI 1.26–1.98, p = 0.09), and (OR 1.35, 95%CI 1.17–2.57, p = 0.03), respectively. Overall, 56 (20.7%) patients experienced a 30-days unplanned readmission. According to univariable analysis, high preoperative CRP and hyperfibrinogenemia were significantly associated with an increased risk of unplanned readmission (OR 2.15, 95%CI 1.15–4.16, p = 0.02; OR 2.18, 95%CI 1.13–4.44, p = 0.02, respectively). Conclusions: In our study, the preoperative immune-inflammation signature described by NLR, PLR, LMR, SII, and CRP showed a low reliability in predicting perioperative course after RC. Preoperative anemia and hyperfibrinogenemia were independent predictors of major complications. Further studies are pending in order to draw definitive conclusions.
Reference46 articles.
1. Witjes, J.A., Bruins, M., Cathomas, R., Compérat, E., Cowan, N.C., Gakis, G., Hernández, V., Lorch, A., Ribal, M.J., and Thalmann, G.N. (2020). EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer 2020. Eur. Assoc. Urol. Guidel. 2020 Ed., presented. 2. European Association of Urology Guidelines on Non-Muscle-Invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ);Babjuk;Eur. Urol.,2022 3. The Comprehensive Complication Index Is Associated with a Significant Increase in Complication Severity between 30 and 90 Days after Radical Cystectomy for Bladder Cancer;Haas;Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol.,2021 4. Prediction of Early (30-Day) and Late (30–90-Day) Mortality after Radical Cystectomy in a Comprehensive Cancer Centre over Two Decades;Korbee;World J. Urol.,2020 5. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index;Vetterlein;Eur. Urol.,2020
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|